While IHC assessment of ER, PR and HER2 status proved valuable in the private sector for selecting early-stage BC patients in SA for cost-effective use of the MammaPrint test generally performed on RNA extracted from surgical biopsies (19), post-surgery identification of a pathogenic BRCA1/2 variant in germline DNA is a major concern. This evidence concerns the gene BRCA1 and breast cancer.